Quest Diagnostics Incorporated

AI-generated fair value estimate for this company.

Method: 10-year unlevered FCF DCF: $1.3B normalized FCF base (FY2025 actual FCF of $1.359B, averaged with FY2026 guidance-implied ~$1.2B); 6% annual FCF growth years 1-5 (company long-term guidance of 4-5% revenue CAGR plus margin/productivity gains); 4% years 6-10; 8% discount rate; 2.5% terminal growth; $5.25B net debt (total debt $5.671B, cash $0.420B); 110.4M diluted shares.

Reasoning: Quest Diagnostics is a mature, capital-light, acquisitive diagnostics company with a stable disclosed FCF profile and explicit long-term management guidance, making a multi-year FCF DCF directly grounded in company targets the most defensible method.